Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 458 participants.

Also called NCT01046110

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 458 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01046110
Other papers using this trial's data
  • Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents Diabetes, obesity & metabolism, 2013-08 DOI, PubMed 23577643, PMC3799217 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Canada, India, Mexico, South Africa, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01046110. Randomized; no masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2010-11 (actual). Results posted on 2015-11-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin
Acronym
BEGIN™
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
insulin degludec
Intervention (Drug)
sitagliptin
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01046110
Content hash
e8053ee9e65ad6f37926d5f428a11dc9c6e83bc373d9aa52b6205d1aa037ad72